

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 12, 2019**

---

**EIDOS THERAPEUTICS, INC.**

(Exact name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-38533**  
(Commission  
File Number)

**46-3733671**  
(IRS Employer  
Identification No.)

**Eidos Therapeutics, Inc.**  
**101 Montgomery Street, Suite 2550**  
**San Francisco, CA 94104**  
(Address of principal executive offices, including zip code)

**(415) 887-1471**  
(Telephone number, including area code, of agent for service)

**Not Applicable**  
(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	EIDX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 8.01. Other Events.**

On September 12, 2019, Eidos Therapeutics, Inc. (the “Company”) announced that the Special Committee of its Board of Directors unanimously rejected the non-binding proposal dated August 8, 2019 from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder (“BridgeBio”), to purchase all of the outstanding common stock of the Company not already owned by BridgeBio.

A copy of the press release issued in connection with the announcement is filed herewith as Exhibit 99.1 hereto.

**Item 9.01. Financial Statements and Exhibits.****(d) Exhibits.**

<u>Exhibit Number</u>	<u>Description</u>
99.1	<a href="#">Press Release dated September 12, 2019</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: September 13, 2019

Eidos Therapeutics, Inc.

By: /s/ Christine Siu

**Christine Siu**  
Chief Financial Officer



## **Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares**

*Advises Stockholders Take No Action at this Time*

San Francisco, CA (September 12, 2019) – Eidos Therapeutics, Inc. (Nasdaq:EIDX) (“Eidos”) announced today that the Special Committee of its Board of Directors (the “Special Committee”) unanimously rejected the non-binding proposal dated August 8, 2019 (the “Proposal”) from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder (“BridgeBio”), to purchase all of the outstanding common stock of the Company not already owned by BridgeBio for a fixed exchange ratio of 1.30 shares of BridgeBio common stock for each share of Eidos common stock.

After a comprehensive review of the Proposal conducted in consultation with its independent financial and legal advisors, including a review of the business and prospects of each of Eidos and BridgeBio, the Special Committee concluded that the Proposal is inadequate and not in the best interests of Eidos’ minority stockholders.

A copy of the letter sent by the Special Committee to BridgeBio on September 12, 2019 in response to the Proposal is included as Annex A to this news release.

Eidos stockholders are advised to take no action at this time.

### **About Eidos Therapeutics, Inc.**

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is developing AG10, a potentially disease-modifying therapy for the treatment of ATTR. For more information, please visit [www.eidostx.com](http://www.eidostx.com). BridgeBio Pharma, Inc., through its wholly-owned subsidiary, BridgeBio Pharma LLC, currently owns approximately 66.6% of the outstanding shares of common stock of Eidos.

### **Cautionary Note Regarding Forward-Looking Statements**

This news release contains statements regarding the Proposal that may be deemed to be “forward-looking statements” within the meaning of applicable securities laws, and Eidos may make related forward-looking statements on or following the date hereof. Forward-looking statements, by their nature, are subject to a variety of inherent risks and uncertainties that could cause actual results to differ materially from the results projected. Many of these risks and uncertainties cannot be controlled by Eidos and include the possibility that discussions with BridgeBio may not result in a transaction and the possibility that any such proposed transaction with BridgeBio may not be entered into or completed on the terms described in the Proposal or at all, including as a result of changes in the business or prospects of Eidos or BridgeBio. As a result, undue reliance should not be placed on these forward-looking statements. Any forward-looking statements in this news release are made only as of the date of this news release.

---

Eidos does not assume any obligation to publicly update any forward-looking statements except as required by law.

**Special Committee Contacts:**

Steve Frankel / Annabelle Rinehart, Joele Frank, Wilkinson Brimmer Katcher, (212) 355-4449

---

**Annex A**

**Response Letter**

September 12, 2019

Brian Stephenson  
Chief Financial Officer  
BridgeBio Pharma, Inc.  
421 Kipling Street  
Palo Alto, CA 94301

Dear Mr. Stephenson,

I refer to your non-binding proposal dated August 8, 2019 (the "Proposal"), proposing to acquire all of the outstanding shares of common stock of Eidos Therapeutics, Inc. ("Eidos") that are not already owned by BridgeBio Pharma Inc. ("BridgeBio") for a fixed exchange ratio of 1.30 shares of BridgeBio common stock for each share of Eidos common stock.

After a comprehensive review of the Proposal conducted in consultation with its independent financial and legal advisors, the Special Committee of the Board of Directors of Eidos (the "Special Committee") has unanimously concluded that the Proposal is inadequate and not in the best interests of Eidos' minority stockholders.

The Special Committee believes that the proposed exchange ratio significantly undervalues Eidos based on the intrinsic value of its key assets and its prospects.

The Special Committee is committed to exploring all options for maximizing stockholder value, and we would be open to evaluating any potentially improved proposals.

Please note that the Special Committee is issuing a press release announcing that it has rejected the Proposal.

On behalf of the Special Committee,

/s/ Rajeev Shah

Rajeev Shah  
Chairman of the Special Committee of the Board of Directors  
Eidos Therapeutics, Inc.